Abstract: A method for generating an immune score, the method comprising the steps of: (i) determining a qualitative and/or quantitative assessment of tumor infiltrating lymphocytes in a sample; (ii) determining a qualitative and/or quantitative assessment of T-cell receptor signaling in the sample; (iii) determining a qualitative and/or quantitative assessment of mutation burden in the sample; (iv) generating, using a predictive algorithm, an immune score based on the determined qualitative and/or quantitative assessment of tumor infiltrating lymphocytes, the determined qualitative and/or quantitative assessment of T-cell receptor signaling, and the determined qualitative and/or quantitative assessment of mutation burden.

Abstract: The present disclosure is directed generally to methods for characterizing response to one or more therapies in patients with clinically apparent cancer, or recurrence of disease in treated cancer patients with no clinically apparent cancer. Also disclosed are methods for detecting and/or treating a cancer using allele imbalance and chromosomal instability.

Abstract: A system and method to extract data from disparate sources and connect them in a meaningful yet de-identified way allows researchers to explore the connected data and build cohorts. There are three parts to the description-first, a description of the data types and their sources and the extraction and transformation process. Second, an overview of the technologies that underpin RDDS. Third, a description of the web-portal that facilitates searching tumors and building cohorts.

Abstract: The present disclosure relates to dual DNA-based and RNA-based next generation sequencing assays, comprising a DNA component comprising an oligonucleotide and a detection probe targeting DNA isolated from the hematological neoplasm and an RNA component comprising oligonucleotide and a detection probe targeting RNA isolated from the hematological neoplasm, as well as the treatment of hematological neoplasms.

Abstract: A method for generating an immune score, the method comprising the steps of: (i) determining a qualitative and/or quantitative assessment of tumor infiltrating lymphocytes in a sample; (ii) determining a qualitative and/or quantitative assessment of T-cell receptor signaling in the sample; (iii) determining a qualitative and/or quantitative assessment of mutation burden in the sample; (iv) generating, using a predictive algorithm, an immune score based on the determined qualitative and/or quantitative assessment of tumor infiltrating lymphocytes, the determined qualitative and/or quantitative assessment of T-cell receptor signaling, and the determined qualitative and/or quantitative assessment of mutation burden.

Abstract: A method for generating an immune score, the method comprising the steps of: (i) determining a qualitative and/or quantitative assessment of tumor infiltrating lymphocytes in a sample; (ii) determining a qualitative and/or quantitative assessment of T-cell receptor signaling in the sample; (iii) determining a qualitative and/or quantitative assessment of mutation burden in the sample; (iv) generating, using a predictive algorithm, an immune score based on the determined qualitative and/or quantitative assessment of tumor infiltrating lymphocytes, the determined qualitative and/or quantitative assessment of T-cell receptor signaling, and the determined qualitative and/or quantitative assessment of mutation burden.

Abstract: A method for characterizing tumor response to immune checkpoint blockade therapy, comprising: (i) obtaining tissue from the tumor; (ii) measuring, using the tissue, expression of one or more cell proliferation gene markers; (iii) determining, based on the measured expression of the one or more cell proliferation gene markers, a proliferation profile of the tumor; (iv) predicting, based on the determined proliferation profile, response of the tumor to immune checkpoint blockade therapy; and (v) determining, by a physician using the predicted response of the tumor to immune checkpoint blockade therapy, a therapy for the tumor.

Abstract: A method for characterizing tumor response to immune checkpoint blockade therapy, comprising: (i) obtaining tissue from the tumor; (ii) measuring, using the tissue, expression of one or more cell proliferation gene markers; (iii) determining, based on the measured expression of the one or more cell proliferation gene markers, a proliferation profile of the tumor; (iv) predicting, based on the determined proliferation profile, response of the tumor to immune checkpoint blockade therapy; and (v) determining, by a physician using the predicted response of the tumor to immune checkpoint blockade therapy, a therapy for the tumor.

Abstract: A method for generating an immune score, the method comprising the steps of: (i) determining a qualitative and/or quantitative assessment of tumor infiltrating lymphocytes in a sample; (ii) determining a qualitative and/or quantitative assessment of T-cell receptor signaling in the sample; (iii) determining a qualitative and/or quantitative assessment of mutation burden in the sample; (iv) generating, using a predictive algorithm, an immune score based on the determined qualitative and/or quantitative assessment of tumor infiltrating lymphocytes, the determined qualitative and/or quantitative assessment of T-cell receptor signaling, and the determined qualitative and/or quantitative assessment of mutation burden.

Abstract: The invention relates to the detection of genomic variants using next generation sequencing platforms, and increasing the positive predictive value and/or sensitivity of detection. The invention relates to methods and systems for detecting the presence or absence of at least one specific genetic variant, including an allelic variant, in a biological sample. Accurately detecting genetic variants can lead to more accurate diagnosis, prognosis, treatment, and/or prevention of various conditions and disease, including cancer.